NEWS
MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
MAIA Biotechnology (NYSE American: MAIA) has announced positive updates from its Phase 2 THIO-101 trial, evaluating THIO sequenced with cemiplimab in advanced non-small cell lung cancer (NSCLC) patients who failed multiple standard therapies. Key highlights include:
1. Six patients have continued treatment for over 12 months, completing up to 21 cycles.
2. The THIO-cemiplimab combination shows significantly lower toxicity compared to standard treatments.
3. Treatment longevity suggests safety, efficacy, and ongoing benefits of MAIA's novel telomere-targeting therapy.
4. Current second-line NSCLC treatments typically last 3-4 months, while THIO patients are showing much longer treatment durations.
These results indicate THIO's potential as a durable and effective treatment for advanced NSCLC patients with options.
1. Six patients have continued treatment for over 12 months, completing up to 21 cycles.
2. The THIO-cemiplimab combination shows significantly lower toxicity compared to standard treatments.
3. Treatment longevity suggests safety, efficacy, and ongoing benefits of MAIA's novel telomere-targeting therapy.
4. Current second-line NSCLC treatments typically last 3-4 months, while THIO patients are showing much longer treatment durations.
These results indicate THIO's potential as a durable and effective treatment for advanced NSCLC patients with options.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment